(Hypertension. 1996;28:806-809.)
© 1996 American Heart Association, Inc.
Articles |
Effect of an Endothelin Antagonist on Hemodynamic Responses to Angiotensin II
the Department of Pharmacology and Cardiovascular Risk Factor Reduction Unit, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
We determined changes in blood pressure, cardiac output, and total peripheral conductance evoked by intravenous infusions of angiotensin II (Ang II) in conscious, unrestrained normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) before and after pretreatment with bosentan, a nonselective endothelin antagonist. Blood pressure was recorded by radiotelemetry and cardiac output by ultrasonic transit-time flow probes. Bosentan per se failed to affect basal blood pressure and evoked only small changes in cardiac output and total peripheral conductance in both strains. The pressor effects of Ang II were exaggerated in SHR compared with WKY. Strikingly, bosentan pretreatment blunted the increases in blood pressure, the fall in cardiac output, and the decreases in conductance evoked by lower doses of Ang II but not higher doses of the peptide. This effect was observed in both rat strains but was more pronounced in SHR. These data suggest that endothelin contributes to the hemodynamic effects of Ang II in both SHR and WKY and that endothelin may contribute to the exaggerated pressor responsiveness of SHR to Ang II.
Key Words: angiotensin II • bosentan • endothelin • rats, inbred SHR • blood pressure • hemodynamics
This article has been cited by other articles:
 |
|
 |
|
  S. J. An, R. Boyd, M. Zhu, A. Chapman, D. R. Pimentel, and H. D. Wang NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts Cardiovasc Res, September 1, 2007; 75(4): 702 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. L. Banes-Berceli, P. Ketsawatsomkron, S. Ogbi, B. Patel, D. M. Pollock, and M. B. Marrero Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1291 - H1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. An, R. Boyd, Y. Wang, X. Qiu, and H. D. Wang Endothelin-1 expression in vascular adventitial fibroblasts Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H700 - H708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Goddard, C. Eckhart, N. R. Johnston, A. D. Cumming, A. J. Rankin, and D. J. Webb Endothelin A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition Are Synergistic via an Endothelin B Receptor-Mediated and Nitric Oxide-Dependent Mechanism J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2601 - 2610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Montanari, A. Biggi, N. Carra, M. Ziliotti, E. Fasoli, L. Musiari, P. Perinotto, and A. Novarini Endothelin-A Receptors Mediate Renal Hemodynamic Effects of Exogenous Angiotensin II in Humans Hypertension, October 1, 2003; 42(4): 825 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rong, D. J. Campbell, and S. L. Skinner Hypertension in the (mRen-2)27 Rat Is Not Explained by Enhanced Kinetics of Transgenic Ren-2 Renin Hypertension, October 1, 2003; 42(4): 523 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yu, V. Gopalakrishnan, T. W. Wilson, and J. R. McNeill Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2511 - H2517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shastri, J. R. McNeill, T. W. Wilson, R. Poduri, C. Kaul, and V. Gopalakrishnan Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H342 - H349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Riggleman, J. Harvey, and C. Baylis Endothelin Mediates Some of the Renal Actions of Acutely Administered Angiotensin II Hypertension, July 1, 2001; 38(1): 105 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Boemke, B. Hocher, N. Schleyer, M. O. Krebs, and G. Kaczmarczyk Hemodynamic, renal, and endocrine responses to acute ETA blockade at different ANG II plasma levels Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1322 - R1331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ballew, S. W. Watts, and G. D. Fink Effects of Salt Intake and Angiotensin II on Vascular Reactivity to Endothelin-1 J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 345 - 350. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. M. Touyz and E. L. Schiffrin Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Rossi, A. Sacchetto, D. Rizzoni, S. Bova, E. Porteri, G. Mazzocchi, A. S. Belloni, M. Bahcelioglu, G. G. Nussdorfer, and A. C. Pessina Blockade of Angiotensin II Type 1 Receptor and Not of Endothelin Receptor Prevents Hypertension and Cardiovascular Disease in Transgenic (mREN2)27 Rats via Adrenocortical Steroid-Independent Mechanisms Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 949 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Rossi, A. Sacchetto, M. Cesari, and A. C Pessina Interactions between endothelin-1 and the renin-angiotensin-aldosterone system Cardiovasc Res, August 1, 1999; 43(2): 300 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Munter, H. Ehmke, and M. Kirchengast Maintenance of blood pressure in normotensive dogs by endothelin Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1022 - H1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Herizi, B. Jover, N. Bouriquet, and A. Mimran Prevention of the Cardiovascular and Renal Effects of Angiotensin II by Endothelin Blockade Hypertension, January 1, 1998; 31(1): 10 - 14. [Abstract] [Full Text] [PDF]
|
|